Boehringer Ingelheim

A doctor with a graphic representation of the lungs
Biotech

Boehringer's phase 3 lung fibrosis trial hits primary endpoint

Boehringer has ended a decade of industrywide failures in idiopathic pulmonary fibrosis with a phase 3 win for a potentially first-in-class drug.
Nick Paul Taylor Sep 16, 2024 8:30am
Amazing landscapes of Appenzell with impressive rock formations and beautiful lakes

Boehringer, Bayer advance lung cancer meds toward Enhertu battle

Sep 9, 2024 4:43pm
MA

Boehringer offers up to $1.3B for checkpoint inhibitor biotech

Jul 29, 2024 10:31am
Graphic of two hands shaking under a red and purple light

Boehringer pays OSE $42M to grab new asset, expand into cardio

May 22, 2024 4:47am
liver

Boehringer signs $1.3B MASH collab with RNA biotech Ochre

Apr 22, 2024 8:45am
pay deal hand over cash licensing transaction money

Boehringer pays €25M for option to Sosei’s schizophrenia drug

Mar 11, 2024 9:10am